Nektar Therapeutics kept at buy by Merrill

Nektar Therapeutics was maintained at buy on news the company will acquire Aerogen, according to Merrill Lynch analysts Hari Sambasivam, Michael Pollard and Mohamed Barrage. Nektar shares closed up $0.27, or 1.56%, on Monday at $17.62 on volume of 471,055 shares compared to the three-month running average of 954,644 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.